Giaconda Suspends Hepaconda Phase II Trial

Giaconda has suspended its Phase IIa trial of Hepaconda for the treatment of hepatitis C in people with Type 1 infection that does not respond to current therapy.

While improvement was demonstrated in liver function among participants in the study, total normalization was not achieved, and further formulation is needed before continuing the study, Giaconda said.

Once the company has secured further funding, it said it will begin a dose-ranging trial to determine an optimum dose for the drug.